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Abstract
Background: Peritoneal metastasis (PM) is considered a terminal and incurable disease. In the last 30 years,
cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) radically changed the therapeutic
approach for these patients and is regarded as the standard of care for pseudomyxoma peritonei from appendiceal
cancer and peritoneal mesotheliomas. Improved survival has also been reported in treating PM from ovarian, gastric,
and colorectal cancers.
However, PM often seriously complicates the clinical course of patients with other primary digestive and non-digestive
cancers. There is increasing literature evidence that helped to identify not only the primary tumors for which CRS
and HIPEC showed a survival advantage but also the patients who may benefit form this treatment modality for the
potential lethal complications.
Our goal is to report our experience with cytoreduction and HIPEC in patients with PM from rare or unusual primary
tumors, discussing possible “unconventional” indications, outcome, and the peculiar issues related to each tumor.
Methods: From a series of 253 consecutive patients with a diagnosis of peritoneal carcinomatosis and treated by CRS
and HIPEC, we selected only those with secondary peritoneal carcinomatosis from rare or unusual primary tumors,
excluding pseudomyxoma peritonei, peritoneal mesotheliomas, ovarian, gastric, and colorectal cancers. Complications
and adverse effects were graded from 0 to 5 according to the WHO Common Toxicity Criteria for Adverse Events
(CTCAE). Survival was expressed as mean and median.
Results: We admitted and treated by CRS and HIPEC 28 patients with secondary peritoneal carcinomatosis from rare or
unusual primary tumors. Morbidity and mortality rates were in line with those reported for similar procedures. Median
survival for the study group was 56 months, and 5-year overall survival reached 40.3 %, with a difference between
patients with no (CC0) and minimal (CC1) residual disease (52.3 vs. 25.7), not reaching statistical significance. Ten
patients are alive disease-free, and eight are alive with disease.
Conclusions: Cytoreduction and HIPEC should not be excluded “a priori” for the treatment of peritoneal metastases
from unconventional primary tumors. This combined therapeutic approach, performed in an experienced center, is safe
and can provide a survival benefit over conventional palliative treatments.
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Background
Patients with peritoneal metastasis (PM) are typically
considered as having a terminal and incurable disease
and justifiably treated only by palliation with a very poor
prognosis [1, 2]. Although ovarian cancer is one of the
most chemotherapy-sensitive solid tumors and one of
the few for which the 5-year survival rate has improved,
long-term survival in most women with locally advanced
disease remains well below 20 % [3–5]. Survival for PM
from non-gynecologic malignancies is even worse. The
EVOCAPE 1 multicenter study reports a median sur-
vival in patients treated with standard surgical and/or
chemotherapy regimens of 6.5 and 5.2 months, res-
pectively, in patients with primary gastric and colorectal
cancer [6].
Over the past two decades, a novel therapeutic ap-
proach has emerged, combining cytoreductive surgery
(CRS), performed to treat all visible disease, and hyper-
thermic intraperitoneal chemotherapy (HIPEC) used to
treat microscopic residual disease [7, 8]. This treatment
radically changed the therapeutic approach for patients
with peritoneal surface malignancies and is nowadays
regarded as the standard of care for pseudomyxoma
peritonei from appendiceal cancer and peritoneal meso-
theliomas [9, 10]. In the last two decades, many studies also
reported with this combined approach improved survival
for the treatment of peritoneal metastases from ovarian
[11–13], gastric [14, 15], and colorectal cancers [16–18].
Peritoneal metastases often complicate also the clinical
course of many patients with other primary digestive
and non-digestive cancers [19, 20]. Due to the rarity of
these conditions, the design of randomized clinical trials
of CRS and HIPEC in these patients is unlikely.
However, PM is frequently long-term confined to the
peritoneal cavity without distant metastases, and death
typically occurs for intractable bowel obstruction, devel-
opment of malignant ascites and mesentery retraction,
that often make it impossible to perform even the
limited palliative surgery like a simple ostomy. A re-
gional approach seems therefore reasonable in selected
patients. Some medical oncologists remain skeptical
mostly because of the complexity of the treatment and
the perceived high complication rate [21] and the need
to treat the patients only in highly specialized centers
[22], but despite skepticism, many are the reports of
CRS and HIPEC in the treatment of PM in these pa-
tients. Expanding literature reports helped to identify
not only the primary tumors for which CRS/HIPEC of-
fers a clear survival advantage but also the patients with
rare or unusual primary (“unconventional”) cancers who
may benefit from this treatment modality for the poten-
tial lethal complications and survival advantage [23–25].
Our goal is to report our single-institution experi-
ence with CRS and HIPEC in patients with PM from
rare or unusual primary tumors, discussing possible
indications, outcomes, and the peculiar issues related
to each tumor, hoping to contribute to extend the ac-
tual knowledge on the treatment of PM by this com-
bined treatment.
Methods
From the clinical records of a series of 253 consecutive
patients admitted in our Institution from November
2000 to December 2013 with a diagnosis of peritoneal
carcinomatosis from various primary tumors and treated
by maximal cytoreduction and HIPEC, we considered
for this study only the patients with a diagnosis of sec-
ondary peritoneal carcinomatosis from “unconventional”
primary tumors. All patients with primary peritoneal
carcinomatosis and with secondary peritoneal carcin-
omatosis from ovarian, gastric, colorectal, and peritoneal
mucinous adenocarcinoma of the appendix (PMCA)
were excluded.
All patients gave informed written consent and had a
clear histologic diagnosis of peritoneal carcinomatosis.
We included only patients with a performance status of
0–2 [26], adequate cardiac, renal, pulmonary and bone
marrow function, and resectable disease. Exclusion
criteria were extraperitoneal spread, other malignan-
cies, unresectable disease, and severe associated med-
ical conditions.
At laparotomy extent of peritoneal carcinomatosis
(PC) was recorded using the peritoneal cancer index
(PCI) [27]. Complete surgical cytoreduction was then
carried out to resect all visible disease.
Completeness of cytoreduction (CC) was recorded as
proposed by Sugarbaker [28].
At the end of the surgical procedure, HIPEC was given
with the closed technique. Four drains were positioned
and connected to a closed extraperitoneal sterile circuit
in which 4 to 6 L of perfusate was circulated by a peri-
staltic pump at a flow rate of 500 mL/min. The circuit
was heated using an external heat exchanger connected
to a heating circuit (EXIPER, Euromedical Italy). HIPEC
was given at a temperature of 42–43 °C for 60 min using
various chemotherapeutic drugs according to the pri-
mary tumor (Table 1). At the end, the abdomen was
washed with 3–4 L of sterile saline solution at 37 °C.
Surgical complications and adverse effects were moni-
tored and graded from 0 to 5 (0—No event; 1—Mild;
2—Moderate; 3—Severe; 4—Life-threatening; 5—Death-
related) according to the World Health Organization Com-
mon Toxicity Criteria for Adverse Events (CTCAE) [29].
The medical oncologic staff planned systemic chemo-
therapy when deemed necessary. Patients were followed
up every 3 months with clinical evaluation and serum-
marker monitoring. Imaging techniques were obtained if
indicated by the patient’s clinical presentation.
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Survival was expressed as mean and median. The
Kaplan-Meier method was used to construct survival
curves, and log-rank test was used to assess the signifi-
cance of the differences (cutoff values p < 0.05).
Results
A total of 28 patients with secondary peritoneal carcin-
omatosis from unconventional primary tumors were ad-
mitted and treated by CRS and HIPEC in our Institution.
The clinical characteristics and type of primary tumor are
reported in Table 1. Mean PCI was 17.1. Twenty-five
patients (89 %) had an optimal cytoreduction (17 CC0 and
8 CC1) while three (10.7 %) had CC2 residual disease.
Peritonectomy procedures lasted a mean of 475 min
(range 300–780) including 60 min of HIPEC. All
operations led to major blood loss (mean 1350 mL, range
500–3900) and required intraoperative blood (mean 4
units, range 2–8) and plasma (mean 6 units, range 2–10)
transfusions.
Most patients (16, 57.1 %) had an uneventful recovery.
The only HIPEC-related adverse event was a grade 1
renal cisplatin toxicity reversed by medical treatment.
Grade 1/2 complications developed in six (21.4 %),
grade 3 in two (7.1 %), and grade 4 in four (14.2 %) pa-
tients. Of the four patients with grade 4 complications,
two underwent a second operation for fistulas (one
colonic and one small bowel) caused by the surgical
maneuvers needed to ablate bowel implants, one for post-
operative bleeding, and one for an abdominal eventration.
Mean postoperative stay was 19.2 days (range 8–71).
Median survival for the study group was 56 months,
and 5-year overall survival reached 40.3 %, with a differ-
ence between CC0 and CC1 patients (52.3 vs. 25.7), not
reaching statistical significance (Fig. 1). Ten patients are
alive disease-free, and eight are alive with disease
(Table 1).
Discussion
Management of peritoneal metastases from breast cancer
Peritoneal carcinomatosis from breast cancer (BC) is rare
but carries high morbidity and mortality [30–32], and no
clear guidelines are available regarding the role of CRS
with or without HIPEC for those patients [33, 34]. Litera-
ture reports are sporadic and only Gusani, one patient in
2008 [1], and Glehen, two patients in 2010 [15], reported
PM from BC treated by CRS and HIPEC. Our study
Table 1 Patients clinical characteristics and survival
PT Age Sex Primary T HIPEC PCI CC FU Surv
1 72 M Sarcoma OXALa 20 1 DODc 12
2 77 F Sarcoma OXALa 16 0 AWDd 11
3 61 M Sarcoma OXALa 14 1 AWDd 9
4 68 F Small bowel CDDPb 26 0 ADFe 23
5 51 M Small bowel CDDPb 15 0 AWDd 23
6 59 M Small bowel CDDPb 20 1 AWDd 8
7 46 F Small bowel CDDPb 7 0 AWDd 3
8 67 M Pancreas OXALc 23 1 ADFe 5
9 67 M Pancreas OXALc 22 2 AWDd 4
10 74 F Pancreas OXALc 3 0 ADFe 8
11 70 F GISTf CDDPb 6 0 ADFe 34
12 53 F GISTf CDDPb 12 0 ADFe 108
13 73 M GISTf CDDPb 20 0 DODc 38
14 58 F Breast IDCg CDDPb 15 0 ADFe 128
15 54 F Breast ILCh CDDPb 22 1 ADFe 74
16 55 F Breast ILCh CDDPb 22 2 DODc 56
17 77 F Breast IDCg CDDPb 24 1 ADFe 45
18 53 F Breast IDCg CDDPb 18 0 ADFe 13
19 60 M Bladder CDDPb 19 2 DODc 9
20 68 F Type II UPSCi CDDPb 5 0 DODc 46
21 56 F Type II UPSCi CDDPb 6 0 DODc 24
22 64 F Type II UPSCi CDDPb 23 0 AWDd 12
23 58 F Type II UPSCi CDDPb 17 0 AWDd 52
24 61 F Type II UPSCi CDDPb 9 0 ADFe 95
25 67 F Type II UPSCi CDDPb 30 1 DODc 15
26 59 F Type II UPSCi CDDPb 29 1 DODc 15
27 65 F Type II UPSCi CDDPb 19 0 DODc 12
28 51 M Lung CDDPb 19 0 DODc 7
aOxaliplatin
bCisplatin
cDied of disease
dAlive with disease
eAlive disease-free
fGastrointestinal stromal tumor
gInvasive ductal carcinoma
hInvasive lobular carcinoma
iType II uterine papillary serous carcinoma
Fig. 1 CRS + HIPEC: Kaplan Meier 5-year survival curves according to
the completeness of cytoreduction (CC) score
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provides previously unavailable information on the treat-
ment of women with PM from BC showing that once the
correct diagnosis has been established [30], these patients
can benefit from treatment and possibly argues against
previous reports describing a poor prognosis. In our pa-
tients, a median 18 years (range 10–30) elapsed after BC
was diagnosed and peritoneal carcinomatosis developed
and accords with previous reports describing breast carcin-
oma as one of the most slowly growing solid tumors given
that metastases may appear even decades after the initial
diagnosis [34, 35]. Of the five patients treated, four
achieved long-term survival, one surviving even for 10 years
with good QOL.
Although CRS and HIPEC cannot be proposed as a
standard care for patients with PM from primary breast
cancer, the survival observed in our small series suggests
that in highly selected patients with no extra peritoneal
disease and in whom surgery can achieve adequate
cytoreduction this combined procedure can offer pa-
tients a promising approach for long-term survival.
Management of peritoneal carcinomatosis from small
bowel adenocarcinoma
Management of patients with PM from small bowel adeno-
carcinoma is unclear with literature reports episodic, even
if PM is a frequent manifestation of small bowel carcinoma
[36, 37]. Typically, these tumors present after a significant
delay in diagnosis for the vagueness of symptoms and im-
aging difficulty. Prognosis is poor with survival varying
from 10 to 40 months. Marchettini and Sugarbaker [38]
reported a median survival of 12 months with two of the
patients treated with CRS and HIPEC with prolonged sur-
vival (57 and 59 months). Chua [39] reported seven cases
treated with CRS and HIPEC (mitomycin C and EPIC
with 5-FU), with a median disease-free survival of
12 months, and also reported a Kaplan-Meier analysis for
a combined group of 19 patients treated with CRS and
HIPEC with a median survival of 29 months. Shen et al.
[40] reported a median survival of 45 months after
treatment with CRS and HIPEC. Another large multi-
institutional experience is reported by the French Surgical
Association [41], with a median survival for patients
treated by CRS and HIPEC of 32 months. In the four
patients treated in our Institution, mean survival was
31.2 months, with two patients alive disease-free at 43 and
22 months and two alive with disease at 33 (pulmonary
metastases) and at 27 (abdominal recurrence) months. All
the series reported show better results when compared to
conventional treatments. Moreover, it has to be consid-
ered that CRS and HIPEC could represent the only valid
surgical option for palliation in obstructed patients, in
whom a simple surgical procedure aimed at bowel decom-
pression is often impossible due to small bowel mesentery
retraction or for the treatment of associated ascites.
Management of peritoneal carcinomatosis from serous
papillary (type II) uterine carcinoma (UPSC)
Endometrial cancer is still the most common cancer of
the female reproductive tract, and its treatment is
surgical, alone or in combination with brachy and/or
radiotherapy. Survival rates are approximately 90 % at
5 years [42]. When compared to type I tumors, type II
endometrial cancers are more likely to present or de-
velop metastatic disease and have a less favorable diag-
nosis. In the presence of peritoneal metastases, the
management becomes more complex and prognosis is
poor, with a median survival not reaching 1 year. Bakrin
[43] reported five patients with endometrial cancer
treated by this combined modality, with a median
survival of 19.4 months. Two patients experienced re-
current disease and died, while three patients are alive
disease-free at 7, 23, and 39 months after treatment.
Glehen [44] in a multi-institutional review of the French
Surgical Association of 1290 patients with peritoneal
metastases from various primary tumors reported the
treatment of 17 patients with uterine adenocarcinoma
and epidermoid carcinoma (4 patients), failing to give
specific survival data for this specific group of patients.
Delotte [42] in 2014 reported CRS and HIPEC in 13
patients with endometrial cancer. Five patients died of
the disease and three are alive with disease at 14, 26, and
28 months, while four patients are alive disease-free at 1,
60, 60, and 124 months. In our Institution, we treated
eight patients with a diagnosis of type II UPSC with CRS
and HIPEC. In four patients, we observed recurrent dis-
ease, and two of them died of the disease at 9 and
13 months, while two are alive with disease at 19 and
26 months. Four patients are alive disease-free at 9, 14,
26, and 33 months. Treatment strategies for stage IV
endometrial cancer remain controversial. Some reports
highlight the histologic characteristics and extent of the
disease as the main prognostic determinants, while
others favor the effects of a more aggressive surgical
cytoreduction. The long-term survival reported in these
observational studies, higher when compared to those
reported in literature with conventional treatments,
seems to justify a more aggressive surgical attitude with
the aim to leave the patients without residual visible
disease.
Management of peritoneal carcinomatosis from
imatinib-resistant GISTosis
Survival of patients with gastrointestinal stromal tu-
mors (GIST) greatly improved with the clinical use of
molecular-targeted therapies [45]. However, the prog-
nosis of imatinib-resistant GIST disseminated to the
peritoneum (spontaneously or during surgery) is poor.
Accepted conventional treatments including palliative
surgery, chemo, and/or radiotherapy are ineffective
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[46]. As with PM from other gastrointestinal or gyneco-
logic epithelial tumors, a strong rationale favors aggres-
sive locoregional treatment in these patients including
peritonectomy procedures combined with HIPEC [47–48]
even if its use is controversial due to the rarity of the con-
dition and the few available published reports [49]. The
results of our small series of three small bowel imatinib-
resistant GIST treated with CRS and HIPEC (two patients
alive disease-free at 34 and 108 months, one patient died
of disease at 38 months) are in line with similar reports
(Table 2) and compare favorably with historical control
groups justifying an effort to optimize treatment of the
primary or recurrent GISTosis.
Management of peritoneal carcinomatosis from other
unconventional miscellaneous tumors
The optimal management of patients with rare and un-
usual primary tumors metastatic to the abdominal cavity
is a matter of intense debate. Systemic chemotherapy for
PM improved but remains limited because of poor diffu-
sion of the drugs into the peritoneum. This is why many
authors [1, 34, 35, 50–55] reported small observational
series of patients with PM from various unconventional
tumors treated by CRS and HIPEC (Table 2). This
combined treatment modality has been used in peri-
toneal metastases from pancreatic, abdominal sarcomas,
gallbladder, liver, cholangiocarcinoma, adrenal, urachal,
Table 2 CRS + HIPEC for PC from various primary tumors
Author (year) Primary tumor Number Overall survival
Median (Months) 1 year (%) 3 years (%) 5 years (%)
Jacks (2005) [37] Small bowel 6 30 - - -
Gusani (2008) [1] Unknown 2 26.2 - 49 -
Breast 1
GIST 6
Gallbladder 1
Liver 1
Adrenal 1
Esophagus 1
Shen (2009) [40] Unknown 2 22.2 66 40 27
Pancreas 5
GIST 11
Sarcoma 10
Gallbladder 3
Adrenal 1
Small bowel 6
Urachus 5
Chua (2009) [3] Small bowel 7 25 57 20 -
Kerscher (2010) [50] Small bowel 3 - - -
Glehen (2010) [15] Unknown 8 34 77 49 37
Breast 2
GIST 3
Sarcoma 28
Liver 2
Adrenal 3
Urachus 4
Small bowel 45
Esophagus 1
Kidney 2
Turrini (2012) [52] Pancreas 1 - - - -
Randle (2013) [48] Sarcoma 10 21 - - 43
Review of the literature
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esophageal, and kidney tumors. In a multi-institutional
review of the French Surgical Association on 1290 cases
of PM from various primary tumors treated with CRS
and HIPEC [41], the unconventional indications were
29. Mortality was 4.1 % with a rate of major (grade 3
and 4) complications of 33 %, similar to those reported
after other major surgical procedures. Obviously, the
numbers are too small to draw any conclusion on sur-
vival figures for each specific primary tumor, but an
overall median survival of 34 months, with a 5-year
disease-free survival of 22 %, compares favorably with
survival figures reported in literature of palliative treat-
ments for the same tumors.
Conclusions
We can conclude that CRS and HIPEC should not be
excluded “a priori” for the treatment of peritoneal me-
tastases from rare or unusual (“unconventional”) primary
tumors. This combined multimodality therapeutic ap-
proach, performed in selected patients in an experienced
peritoneal surface malignancy center, is safe and has
shown to provide not only a better palliation but also a
survival benefit over conventional palliative treatments.
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